BresaGen signs two new contracts
Tuesday, 02 August, 2005
Adelaide-based BresaGen (ASX:BGN) has signed two new contracts under its protEcol Services business unit.
The first is with Irish based Opsona Therapeutics, which will use BresaGen to progress process development of its pre-clinical immunomodulator, OPN-201. The second contract is with US firm Pepgen Corporation, which first partnered with BresaGen in 2004, to develop a process for Pepgen to produce a novel interferon alpha analog, Neoferon.
Under the contract, BresaGen will further develop the E. coli-based process and produce GLP recombinant protein.
Light at night can increase heart disease risk
Being exposed to bright light at night can significantly increase your chances of developing...
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
